SureTrader Nadex Advertisement
Home > Boards > US OTC > Cannabis >

ProText Mobility, Inc. (TXTM)

Add TXTM Price Alert      Hide Sticky   Hide Intro
Moderator: MIKEY501, kimokahu, dcsteve, knowmystuff, momentum2015, F.STOTLER
Search This Board: 
Last Post: 2/23/2017 5:54:17 PM - Followers: 468 - Board type: Free - Posts Today: 99


Stock Symbol: TXTM

On December 31, 2016, we completed a share exchange with Plandaí Biotechnology South Africa (Pty) Ltd. in which we acquired 100% of the outstanding stock of Plandaí. As a result of this transaction, the shareholders of Plandaí became the majority owners of Protext Mobility and Plandaí elected to become the “successor issuer” for SEC reporting purposes.

Plandaí is a research company headquartered in the Mpumalanga province of South Africa, approximately an hour west of the Kruger National Park in the northeast part of the country. Plandaí has the worldwide exclusive license to develop and market pharmaceutical applications for Phytofare® extracts, including the green-tea derived Catechin Complex that has been clinical proven to be 10-times more bioavailable than generics.

Green tea catechins have demonstrated a wealth of clinical health benefits and can be found in many different nutraceutical products, especially for weight loss. In laboratory, in vitro studies, catechins have shown remarkable potential for treating viruses, bacterial infections, inflammation, preventing certain cancers, and regulating blood sugar levels. However, like many botanical extracts, green tea has notoriously low bioavailability. Meaning, very little of what is consumed makes it intact to the blood stream. Phytofare®, with its superior bioavailability, can deliver all 8 catechins to the blood stream at therapeutic levels, where they remain active for over 24 hours.

What this means is that we have the potential, for the first time, to use an all-natural extract for pharmaceutical applications.

Commencing in early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in controlling blood sugar levels in diabetics. Mauritius has the highest per-capita incidence levels of diabetes in the world. Assuming the trials results are favorable, we anticipate having a product market-ready by Q4 2017 specific for managing insulin.

Future clinical trials will involve both the Catechin Complex and a citrus-based Limonoid Complex as we pursue treatments for inflammation, viruses (including malaria), soft-tissue injuries, and capillary integrity.


Plandai Biotechnology South Africa (pty) Ltd, recently acquired by Protext Mobility, Inc, is publicly traded on the OTC Markets under the ticker symbol "TXTM"

The Company is actively engaged in the research and clinical testing of “bioceutical” products—all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Our initial product, Phytofare® Catechin Complex, has been clinically proven to have 10 times greater bioavailability over generic catechin extracts. Commencing early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in regulating blood sugar levels in diabetics. The trial will be conducted in the island country of Mauritius which has the highest per capita incidence of diabetes in the world. Assuming a favorable result, we anticipate having a product market ready by the end of 2017 and eventually filing for product claims with the US Food and Drug Administration.

We are majority-owned by Plandaí Biotechnology, Inc. (OTCQB: PLPL), a London-based holding company that controls over 8,000 acres of tea estate in the province of Mpumalanga, South Africa, and owns a 100,000 square foot manufacturing facility that produces Phytofare®.

PROTEXT MOBILITY CLOSES ACQUISTION OF PLANDAI BIOTECHNOLOGY WHOLLY OWNED SUBSIDIARY (PLPL-SA) Boca Raton, FL – January 11th, 2016 - Protext Mobility Inc. (OTCPINK: TXTM) announced that it has completed the acquisition of Plandaí Biotechnology South Africa (PTY) LTD “Plandaí SA”, a wholly owned subsidiary of Plandaí Biotechnology, Inc., publicly traded under the ticker (PLPL). Plandaí SA is a biotechnology firm engaged in the research and development of botanical extracts, such as green tea, aimed at treating metabolic disorders, including diabetes. The parent company of Plandaí SA, Plandaí Biotechnology, Inc., is the culmination of over 10 years of research and development in the field of plant extracts with principle holdings including raw materials processing, infrastructure, production facilities, farms and land totaling 7500 acres in the province of Mpumalanga, South Africa. Plandaí SA was established in 2014 by parent company, Plandaí Biotechnology, Inc. to provide a platform for expanding the research of Plandaí’s proprietary Phytofare® extracts into pharmaceutical applications. Phytofare® has been clinically proven in studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the parent company, Plandaí Biotechnology, focuses on selling Phytofare® as an ingredient to manufacturers in the nutraceutical industry, Plandaí SA will target the pharmaceutical market with a finished product. Plandaí SA has the exclusive license and rights to develop, manufacture, and sell all current and future Phytofare® extracts for the pharmaceutical market worldwide. The first targeted product will focus on treating diabetes by regulating blood sugar levels with an expectation of being market ready in the latter half of 2017. David Lewis, Director of Protext Mobility, commented, “We’re pleased to announce this share exchange with Plandaí SA and we’re confident that this transaction will create exciting new opportunities for the company. Plandaí has a proven track record for delivering high-quality, science-based botanical ingredients that fit perfectly into the bio-pharmaceutical space. With the first human clinical trial set to commence in the first quarter of 2017, we anticipate great things in the coming months.” The Company is also pleased to announce the appointment of Mr. Roger Duffield to the role of Chief Executive Officer and Chairman of the Board. Mr Duffield is a seasoned executive, responsible for the massive undertaking and successful development of the 7500 acre Senteeko Estate. Mr.Duffield, is a hands on CEO, currently in South Africa, overseeing the 100,000 square foot factory, and preparing for the upcoming human clinical trial being conducted by Plandai SA. 

Plandai Biotechnology South Africa

Plandaí Biotechnology South Africa (Pty) Ltd, recently acquired by Protext Mobility, Inc.(OTCPINK: TXTM) is a South Africa-based research company focusing on the development of pharmaceutical applications for botanical drugs.

Plandaí South Africa has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. What this means is that Phytofare® can deliver a therapeutic level of catechins to the system where they remain active for over 24 hours. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets. There is a strong body of scientific research that points to the effectiveness of green tea catechins in managing obesity, high blood pressure, diabetes and other diet-related diseases. Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and the reduction in fat mass, tricylglycerides, free fatty acids and total cholesterol. The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins. Human studies have shown anti-obesity, anti-diabetic and cardio-protective effects of green tea catechins (1).

However, as we all know, like many botanical ingredients green tea is poorly absorbed into the blood stream, rendering it an ineffective primary control therapy. Phytofare®, on the other hand, which has ten-times greater absorption, may very well provide an inexpensive, all-natural solution to these diseases. Our clinical trial is designed to build on this prior research and show the benefits of Phytofare® in managing glucose levels, with a short-term goal of having a consumer-ready capsule product by Q4, 2017.

Worldwide as of 2015, 415 million people had diabetes, with the number growing to over 642 million people in 2016, with Type II Diabetes making up about 90% of the cases. In 2014, the IDF estimated that diabetes resulted in 4.9 million annual deaths.

1. F. Thielecke, M. Boschmann / Phytochemistry (2009) “The potential role of green tea catechins in the prevention of the metabolic syndrome” ?

Roger Duffield - President & CEO

Roger Duffield has a significant background in the development and management of start-ups, private and public companies, especially in the United States, Europe and South Africa. His previous contributions in the United States public sector include Klinair Technologies Inc. and Rhombic Inc. relating to energy and hydrocarbon technologies. Through his extensive involvement with research and development programs with a number of academic institutions, including Penn State, University of Southern California, University of Washington, and the University of Limerick, Ireland, he was awarded two honorary Russian doctorates in Natural Sciences from the University of Moscow and Novosibirsk. In 2001 the Foundation for International Services, California recognized a degree in BSc. Chemical Engineering.

In 2001 he co-founded Global Energy Solutions Corporation Limited, Dublin, Ireland, recently acquired by Plandaí Biotechnology, Inc., and in 2003, the USA-based Research Company, CRS Technologies Inc. Mr. Duffield now heads this group of companies specializing, through private and public investment in the farming and recovery of highly valuable botanical extracts with unique characteristics.'

Contact Details

9 Palm Street
White River 1240
South Africa

 P: +1 (435) 881 3611
 E: [email protected]





American Stock Transfer & Trust Company
Transfer Agent
6201 15th Avenue
Brooklyn, NY 11219

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TXTM News: USMJ PPS Holds Up Against Short Selling – Short Squeeze Potential To Push Past $0.0017 Resistance 02/03/2017 09:38:17 AM
TXTM News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 01/27/2017 10:34:38 AM
TXTM News: Securities Registration (section 12(g)) (8-a12g) 01/27/2017 10:29:43 AM
TXTM News: Current Report Filing (8-k) 01/19/2017 11:32:53 AM
TXTM News: Plandai Biotechnology Announces Share Exchange Between Protext Mobility and Plandai's South Africa Subsidiary 01/10/2017 07:43:54 AM
#28852  Sticky Note Research into 2017 Revenue Streams for $TXTM-PLSA and $PLPL DD_dempsey 02/21/17 10:08:13 PM
#16819  Sticky Note *** 1-11-2017 TXTM ACQUISITION/MERGER NEWS OUT *** MIKEY501 01/11/17 12:40:56 PM
#15818  Sticky Note BIG DD TXTM ACQUISTION polochinos 12/23/16 01:10:07 PM
#12849  Sticky Note Protext Mobility Inc (TXTM) Launches New Website and Carjockey2 12/12/16 02:18:20 PM
#11243  Sticky Note NEWS 12/7: halt debt conversions for a period dcsteve 12/09/16 01:59:07 PM
#29139   Watch the next share update if they decide StoptheInsanity9 02/23/17 05:54:17 PM
#29138   Trusted source telling me pennyland on this one. vantillian 02/23/17 05:45:55 PM
#29137   Hey good news company staying in touch! Got Holdemorfoldem 02/23/17 04:55:51 PM
#29136   Yup just churning in this zone coiling tighter WIlsonWalker 02/23/17 04:11:35 PM
#29135   TXTM been trading clean this past week. RavenDusk1 02/23/17 04:08:25 PM
#29134   Really starting to question this company been here Going2Pot 02/23/17 04:06:41 PM
#29133   Fliptards whitie 02/23/17 04:00:56 PM
#29132   News please!! : ) Jsal20 02/23/17 03:55:01 PM
#29131   Feeling bagholderish Rymar3 02/23/17 03:44:10 PM
#29130   $TXTM got back in here. Hearing things are vantillian 02/23/17 03:42:56 PM
#29129   Thank you Max! RavenDusk1 02/23/17 03:38:45 PM
#29128   I sincerely appreciate all the .0018s today. MAXMILLION 02/23/17 03:35:40 PM
#29127   I thought I saw that public comment was ShawnyD 02/23/17 03:23:50 PM
#29126   Frankly, it's a FANTASTIC Trading day for $TXTM DD_dempsey 02/23/17 03:21:16 PM
#29125   You're fine Raven... MAXMILLION 02/23/17 03:08:30 PM
#29124   It's been all retail flipping in and out. MAXMILLION 02/23/17 03:02:12 PM
#29123   too much manipulation, dilution? Rymar3 02/23/17 02:56:31 PM
#29122   so by the 28th of fed. should we GodMadeWeed 02/23/17 02:44:15 PM
#29121   It'd be nice to see a .0021 close Tulaz1 02/23/17 02:40:54 PM
#29120   TXTM great accumulation this week! RavenDusk1 02/23/17 02:29:43 PM
#29119   Ask just thinned out with those sells on flemdog33 02/23/17 01:45:49 PM
#29118   Is this one ready to pop yet? Tulaz1 02/23/17 01:41:18 PM
#29117   Did somebody say handouts?! Mwensinger 02/23/17 01:35:45 PM
#29116   I'd love some handouts.. I've had to buy whynot1790 02/23/17 01:25:12 PM
#29115   Did you get any of the handouts? I flemdog33 02/23/17 01:18:19 PM
#29114   TXTM just handing out shares!!!! Management has to StoptheInsanity9 02/23/17 01:15:14 PM
#29113   TXTM Million-Share Teen-Ask now in Strong-Hands! Black Solvency 02/23/17 01:05:21 PM
#29112   One was me at 2.5mm Just to test. NITE Reluctant Observer 02/23/17 01:01:20 PM
#29111   TXTM .002 On Balance Volume at +1.5-Billion; WOW! Black Solvency 02/23/17 12:59:16 PM
#29110   L2 looking extremely thin pbrida 02/23/17 12:58:41 PM
#29109   $TXTM A few nice slaps at .002 over trading.jeff 02/23/17 12:56:21 PM
#29108   I am not a trader or a flipper Reluctant Observer 02/23/17 12:50:22 PM
#29107   NITE hidden shelf. Lol Reluctant Observer 02/23/17 12:49:14 PM
#29105   For the peeps that don't believe...that should be proof. Reluctant Observer 02/23/17 12:46:25 PM
#29104   Hoping you get zero since you then kill flemdog33 02/23/17 12:45:43 PM
#29103   I will take it up to .002 to Reluctant Observer 02/23/17 12:45:24 PM
#29102   The reluctant observer going in again to shine Reluctant Observer 02/23/17 12:44:20 PM
#29101   I will be happy with .05 dld_ip 02/23/17 12:42:17 PM
#29100 Calvin Hobbes 02/23/17 12:41:16 PM
#29099   Black Solvency seeks Large-Blocks TXTM at .0016 or Black Solvency 02/23/17 12:39:25 PM
#29098   $TXTM will see pennies!!!!!!!!!!!! Mark this post!!!!!!!!!!!!!!!!!!! kimokahu 02/23/17 12:37:26 PM
#29097   South Africa Cannabis only administered in Refined Pharmaceutical Forms. Black Solvency 02/23/17 12:32:00 PM
#29096   Loaded me some more here today let's see Going2Pot 02/23/17 12:26:31 PM
#29095   It will go just a matter of time now whynot1790 02/23/17 12:16:53 PM
#29094   Seriously. Everyone just waiting for PR Mwensinger 02/23/17 12:11:37 PM
#29093   This thing is so stubborn. Need some volume. Mr Rollup 02/23/17 12:09:25 PM
#29092   Nice day forming here. Break .0025 and off whynot1790 02/23/17 11:56:53 AM
#29091   TXTM nice day , higher lows RavenDusk1 02/23/17 11:44:32 AM
#29090   I don't see a run happening today but Mwensinger 02/23/17 11:43:53 AM
#29089   Look how it moves on low volume, so pbrida 02/23/17 11:33:47 AM